Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
859
Completed, industry sponsors, Hematology and blood cancers, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting155
- Completed859
859 trials
Showing 1 to 25, recently updated first.
- To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisPivotal-lookingCompleted
Akebia TherapeuticsIndustry
NCT06901505 · 353 participants · Start Jul 24, 2025 · Primary completion Aug 12, 2026
Drug: Erythropoiesis-Stimulating Agent (ESA); Vadadustat · For: Anemia of Chronic Kidney Disease
Sites: Montgomery, Alabama; Hartford, Connecticut; Middlebury, Connecticut · 18 sites in all
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLPivotal-lookingCompleted
Acerta Pharma BVAstraZeneca (AZN)
NCT02475681 · 535 participants · Start Jun 26, 2015 · Primary completion Feb 8, 2019
Drug: Acalabrutinib; Obinutuzumab and 1 more · For: Chronic Lymphocytic Leukemia
Sites: Goodyear, Arizona; Phoenix, Arizona; Anaheim, California · 155 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05133531 · 202 participants · Start Aug 1, 2022 · Primary completion Sep 28, 2026
Drug: Ravulizumab; Pozelimab and 2 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Whittier, California; Santo André, Brazil; São Paulo, Brazil · 68 sites in all
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantPivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04543591 · 148 participants · Start Dec 10, 2020 · Primary completion Sep 19, 2025
Drug: Ravulizumab · For: Thrombotic Microangiopathy
Sites: Tampa, Florida; Grosse Pointe Farms, Michigan; Durham, North Carolina · 66 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03652064 · 395 participants · Start Nov 6, 2018 · Primary completion May 7, 2024
Drug: Daratumumab; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Cerritos, California; Jacksonville, Florida; Fort Wayne, Indiana · 114 sites in all
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)Pivotal-lookingCompleted
OctapharmaIndustry
NCT04502030 · 247 participants · Start Oct 5, 2020 · Primary completion Sep 19, 2025
Drug: Panzyga · For: Chronic Lymphocytic Leukemia; Hypogammaglobulinemia
Sites: St. Petersburg, Florida; Columbus, Georgia; Macon, Georgia · 84 sites in all
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsPivotal-lookingCompleted
CSL BehringIndustry
NCT06738485 · 62 participants · Start Jan 9, 2025 · Primary completion Sep 23, 2026
Drug: Recombinant single-chain factor VIII (rVIII-SingleChain) · For: Congenital Hemophilia A
Sites: Hefei, China; Beijing, China; Chongqing, China · 20 sites in all
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03362177 · 165 participants · Start Sep 30, 2019 · Primary completion Jan 25, 2024
Drug: Romiplostim · For: Chemotherapy-induced Thrombocytopenia
Sites: Jonesboro, Arkansas; Anaheim, California; Orange, California · 117 sites in all
- A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03069352 · 211 participants · Start May 29, 2017 · Primary completion Feb 15, 2019
Drug: Placebo; Venetoclax and 1 more · For: Acute Myeloid Leukemia (AML)
Sites: Tampa, Florida; Louisville, Kentucky; Pittsburgh, Pennsylvania · 109 sites in all
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03194893 · 50 participants · Start Jul 5, 2017 · Primary completion Sep 18, 2025
Drug: Alectinib; Crizotinib · For: Neoplasms
Sites: Orange, California; Boston, Massachusetts; Caen, France · 29 sites in all
- Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingCompleted
Principia Biopharma, a Sanofi CompanyIndustry
NCT04562766 · 232 participants · Start Dec 14, 2020 · Primary completion Jan 15, 2025
Drug: Rilzabrutinib; Placebo · For: Immune Thrombocytopenia
Sites: Los Angeles, California; San Francisco, California; Torrance, California · 155 sites in all
- Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03754790 · 281 participants · Start Jan 9, 2019 · Primary completion Sep 14, 2026
Drug: Fitusiran · For: Hemophilia
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 79 sites in all
- Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03974113 · 32 participants · Start Jan 28, 2020 · Primary completion Aug 4, 2026
Drug: Fitusiran · For: Hemophilia
Sites: Los Angeles, California; Hackensack, New Jersey; Cleveland, Ohio · 16 sites in all
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT03182244 · 276 participants · Start Oct 25, 2017 · Primary completion Dec 25, 2023
Drug: Gilteritinib; Cytarabine and 4 more · For: AML With FLT3 Mutation
Sites: Beijing, China; Changchun, China; Changsha, China · 49 sites in all
- A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseasePivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03745287 · 63 participants · Start Nov 27, 2018 · Primary completion Jul 7, 2025
Drug: Exa-cel · For: Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies
Sites: Palo Alto, California; Chicago, Illinois; New York, New York · 17 sites in all
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinPivotal-lookingCompleted
Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
NCT06142552 · 124 participants · Start Dec 27, 2023 · Primary completion Oct 8, 2025
Drug: FRSW117 · For: Severe Hemophilia A
Sites: Beijing, China; Changsha, China; Chongqing, China · 28 sites in all
- Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04008706 · 552 participants · Start Sep 17, 2019 · Primary completion Nov 4, 2025
Drug: Acalabrutinib · For: Chronic Lymphocytic Leukemia
Sites: Chandler, Arizona; Long Beach, California; Redlands, California · 108 sites in all
- The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive SurgeryPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06507436 · 127 participants · Start Jul 31, 2024 · Primary completion Aug 14, 2026
Drug: Herombopag tablets; Herombopag placebo tablets · For: Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Sites: Shanghai, China
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04158648 · 73 participants · Start Feb 10, 2020 · Primary completion Oct 30, 2021
Drug: Emicizumab · For: Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor; Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor; Hemophilia A
Sites: Los Angeles, California; Atlanta, Georgia; Indianapolis, Indiana · 22 sites in all
- A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)Pivotal-lookingCompleted
Nanogen Pharmaceutical Biotechnology Joint Stock CompanyIndustry
NCT05585645 · 214 participants · Start Aug 8, 2019 · Primary completion Nov 23, 2022
Drug: Stimus (NNG-DEPO) · For: Anemia; Chronic Kidney Disease Requiring Chronic Dialysis
Sites: Ho Chi Minh City, Vietnam
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03106779 · 233 participants · Start Oct 26, 2017 · Primary completion May 25, 2020
Drug: Asciminib; Bosutinib · For: Chronic Myelogenous Leukemia
Sites: Chicago, Illinois; Beech Grove, Indiana; Baltimore, Maryland · 88 sites in all
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03938792 · 188 participants · Start Mar 9, 2020 · Primary completion Apr 29, 2025
Drug: PF-06741086 · For: Hemophilia A; Hemophilia B
Sites: Tampa, Florida; Iowa City, Iowa; New Hyde Park, New York · 62 sites in all
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04889430 · 34 participants · Start Jan 17, 2022 · Primary completion Apr 11, 2026
Drug: Iptacopan · For: Atypical Hemolytic Uremic Syndrome
Sites: Los Angeles, California; Orange, California; Sacramento, California · 36 sites in all
- Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel DiseasePivotal-lookingCompleted
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT07739368 · 122 participants · Start Sep 1, 2021 · Primary completion Feb 20, 2025
Drug: Ferric Maltol; Placebo Oral Capsule · For: Iron Deficiency Anaemia
Sites: Nanjing, China
- Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyPivotal-lookingCompleted
CSL BehringIndustry
NCT06399289 · 23 participants · Start Jul 28, 2024 · Primary completion Jul 7, 2026
Drug: Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) · For: Hemophilia B
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 7 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.